

1 **Expression of varicella-zoster virus VLT-ORF63 fusion transcript induces broad viral**
2 **gene expression during reactivation from neuronal latency**

3

4 Werner J. D. Ouwendijk^{1, 7}, Daniel P. Depledge^{2, 7}, Labchan Rajbhandari³, Tihana Lenac
5 Rovis⁴, Stipan Jonjic⁴, Judith Breuer⁵, Arun Venkatesan³, Georges M. G. M. Verjans¹, and
6 Tomohiko Sadaoka^{6*}

7

8 **Author Affiliation:**

9 ¹Department of Viroscience, Erasmus Medical Centre, 3015 CN, Rotterdam, The
10 Netherlands.

11 ²Department of Medicine, New York University School of Medicine, NY 10016, United
12 States of America.

13 ³Division of Neuroimmunology and Neuroinfectious Diseases, Department of Neurology,
14 Johns Hopkins University School of Medicine, 600 N. Wolfe St., Meyer 6-113, Baltimore,
15 Maryland 21287, United States of America.

16 ⁴Centre for Proteomics, Faculty of Medicine, University of Rijeka, Rijeka 51000, Croatia

17 ⁵Division of Infection and Immunity, University College London, London, WC1E 6BT,
18 United Kingdom.

19 ⁶Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate
20 School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.

21 ⁷These authors contributed equally: Werner J. D. Ouwendijk and Daniel P. Depledge.

22

23 ***Corresponding Author:**

24 Tomohiko Sadaoka, DDS, PhD

25 Assistant Professor, Division of Clinical Virology, Center for Infectious Diseases

26 Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-
27 0017, Japan.

28 Email: tomsada@crystal.kobe-u.ac.jp

29

30 **ORCID identifier:**

31 Werner J. D. Ouwendijk, <https://orcid.org/0000-0001-8393-296X>

32 Daniel P. Depledge, <https://orcid.org/0000-0002-4292-0599>

33 Labchan Rajbhandari, <https://orcid.org/0000-0002-9252-2580>

34 Tihana Lenac Rovis, <https://orcid.org/0000-0002-3299-1334>

35 Stipan Jonjic, <https://orcid.org/0000-0001-5003-3108>

36 Judith Breuer, <https://orcid.org/0000-0001-8246-0534>

37 Arun Venkatesan, <https://orcid.org/0000-0002-9335-7361>

38 Georges M. G. M. Verjans, <https://orcid.org/0000-0002-2465-2674>

39 Tomohiko Sadaoka, <http://orcid.org/0000-0001-7951-6904>

40

41 **Author Contributions:**

42 W.J.D.O., D.P.D., and T.S. designed the study, performed the experiments and analyzed

43 the data. W.J.D.O., D.P.D., G.M.G.M.V., and T.S. wrote the paper. L.R., T.L.R., S.J., and A.V.

44 contributed to new reagents/analytic tools. J.B. and G.M.G.M.V. provided additional

45 input into the study. All authors read and approved the final paper.

46

47 **Summary**

48 Varicella-zoster virus (VZV) establishes lifelong neuronal latency in most humans world-
49 wide, reactivating in one-third to cause herpes zoster and occasionally chronic pain. How
50 VZV establishes, maintains and reactivates from latency is largely unknown. Latent VZV
51 gene expression is restricted to VZV latency-associated transcript (VLT) and open reading
52 frame 63 (ORF63) in naturally VZV-infected human trigeminal ganglia (TG). Notably,
53 these transcript levels positively correlated suggesting co-regulated transcription during
54 latency. Here, we used direct RNA-sequencing to identify fusion transcripts that combine
55 VLT and ORF63 loci (VLT-ORF63) and are expressed during both lytic and latent VZV
56 infections. Furthermore, real-time PCR, RNA *in situ* hybridization and 5' rapid
57 amplification of cDNA ends (RACE) all confirmed VLT-ORF63, but not canonical ORF63,
58 expression in human TG. During lytic infection, one of the two major VLT-ORF63 isoforms
59 encodes a novel fusion protein combining VLT and ORF63 proteins (pVLT-ORF63). *In vitro*,
60 VLT is transcribed in latently VZV-infected human sensory neurons, whereas VLT-ORF63
61 expression is induced by reactivation stimuli. Moreover, the pVLT-ORF63-encoding VLT-
62 ORF63 isoform induced transcription of lytic VZV genes. Collectively, our findings show
63 that VZV expresses a unique set of VLT-ORF63 transcripts, potentially involved in the
64 transition from latency to lytic VZV infection.

65

66 **Main Text**

67

68 The ubiquitous human neurotropic alphaherpesvirus (α HV) varicella-zoster virus (VZV)
69 establishes lifelong latency in sensory neurons of dorsal root and cranial nerve ganglia,
70 as well as autonomic and enteric ganglia^{1,2}. VZV reactivates in about one-third of latently
71 infected individuals to cause herpes zoster (HZ), a debilitating disease often complicated
72 by post-herpetic neuralgia (PHN)^{3,4}. The incidence and severity of HZ is closely related to
73 declining VZV-specific T-cell immunity by natural senescence⁵, and immunosuppressive
74 diseases⁶. However, the mechanisms governing how VZV reestablishes a lytic infection
75 from latency in neurons, especially the identity of the viral gene(s) that facilitate
76 reactivation in response to cellular signaling, remain unknown.

77 During latency in human trigeminal ganglia (TG), VZV gene expression is restricted
78 to the VZV latency-associated transcript (VLT) and ORF63⁷. VLT is a polyadenylated RNA
79 comprising five exons that lie partially antisense to VZV ORF61, the infected cell
80 polypeptide 0 (ICP0) homologue conserved among α HV. Based on genomic location and
81 expression pattern, VLT is considered a homologue of the latency-associated transcripts
82 (LATs) encoded by all other well-studied neurotropic α HVs⁸. While VLT is the most
83 prevalent and abundant VZV transcript expressed in human TGs, lower levels of ORF63
84 RNA have also been reported in up to 70% of examined latently VZV-infected ganglia^{7,9}.
85 This apparent expression of two distinct viral transcripts during latency is unique among
86 well-studied α HV. Expression levels of VLT and ORF63 transcripts correlate significantly⁷,
87 suggesting co-regulated expression of both transcripts during *in vivo* latency, and that

88 these transcripts and/or their encoded proteins may play an important role in the VZV
89 latency and reactivation cycle. VLT is expressed during both latent and lytic VZV
90 infection⁷. Intriguingly, VLT isoforms expressed during lytic VZV infection differ
91 extensively from the latent VLT isoform in that they contain additional upstream exons
92 and show evidence of alternative splicing by exon skipping or intron retention⁷.
93 Furthermore, a long-read cDNA sequencing approach recently reported the presence of
94 lytic VLT isoforms splicing into ORF63 during lytic VZV infection¹⁰, raising the possibility
95 that single transcripts may link the VLT and ORF63 loci.

96 Here, we set out to characterize the expression patterns and functional
97 importance of VLT and ORF63 during lytic and latent infections. We applied direct RNA
98 sequencing (dRNA-seq) on nanopore arrays¹¹ to examine lytically VZV-infected epithelial
99 cells and discovered a novel set of VLT-ORF63 fusion transcripts, which are also present
100 in latently VZV-infected human TG and our recently improved *in vitro* VZV human
101 neuronal latency model based on human induced pluripotent stem cell (iPSC)-derived
102 sensory neurons (HSN)^{7,12}.

103

104 **RESULTS**

105

106 ***Identification of multiple VLT-ORF63 fusion transcripts in lytically VZV-infected cells.***

107 Sequencing of full-length RNAs, including direct RNA sequencing (dRNA-Seq), is
108 particularly useful for disentangling complex loci at which multiple RNA isoforms
109 overlap^{13,14}. dRNA-Seq analysis of lytically VZV-infected human retina epithelial (ARPE-

110 19) cells identified numerous VLT isoforms, many of which utilized one or more major
111 upstream exons, designated A, B, and C, upstream of the core VLT region (exon 1-5) that
112 defines the latent isoform (**Fig. 1a**)⁷. We additionally identified several relatively
113 abundant transcripts that spanned the VLT and ORF63 loci, hereafter referred as VLT-
114 ORF63 fusion transcripts (**Fig. 1a**). Two major VLT-ORF63 isoforms (i.e. VLT-ORF63a and
115 VLT-ORF63b) represent alternatively spliced variants of a lytic VLT isoform composed of
116 the VLT core region, an additional upstream exon (A, B or C) and the complete ORF63
117 transcript. VLT-ORF63a and VLT-ORF63b differ from each other by skipping or retention
118 of VLT exon 5, respectively. Both isoforms use a splice acceptor site located 71
119 nucleotides (nt) upstream of the ORF63 coding sequence (CDS), located within the 5'-
120 untranslated region (UTR) of canonical ORF63^{15,16}. A third major isoform (VLT-ORF63c)
121 utilizes a unique transcription start site (TSS), not used by any of the other lytic VLT
122 isoforms, proximal to exon 5 (**Fig. 1a**)⁷.

123 To investigate the effect of cell type on the expression patterns of VLT, VLT-ORF63
124 and ORF63 during VZV infection, we assayed our *in vitro* HSN model that supports both
125 lytic and latent VZV infection¹². The low yields of viral RNA obtained from infected HSN
126 cultures necessitated the use of nanopore cDNA sequencing (cDNA-Seq) rather than
127 dRNA-Seq. Notably, the same VLT and VLT-ORF63 isoforms were detected in lytically VZV-
128 infected HSN and ARPE-19 cells by both nanopore sequencing (**Fig. 1a**) and RT-qPCR (**Fig.**
129 **1b**) using primer sets spanning VLT-ORF63 isoform-defining exons (**Supplementary Fig.**
130 **1 and Supplementary Table 1**). Collectively, these data indicate that identical repertoires

131 of VLT and VLT-ORF63 isoforms are expressed during lytic VZV infection in human sensory
132 neurons and epithelial cells.

133

134 ***VLT-ORF63 explains co-regulated VLT and ORF63 transcription in latently VZV-infected***
135 ***human TG.***

136 Detailed RT-qPCR was performed on four human TG specimens to determine whether
137 ORF63 RNA detected in latently VZV-infected TG is derived from canonical ORF63 or VLT-
138 ORF63s (**Supplementary Table 2**). Consistent to our earlier study⁷, VLT was detected in
139 all TG analyzed while ORF63 CDS region was detected in 3 of 4 specimens (**Fig. 2a**). No
140 transcripts were detected using primer set ORF63UTR (**Supplementary Fig. 1**), which
141 targets the 5' UTR of canonical ORF63 that is absent in all VLT-ORF63 transcripts.
142 However, splice junction usage between VLT exon 4 or 5 and ORF63 was detected in all
143 ORF63 CDS^{POS} TGs (**Fig. 2a**).

144 We next performed multiplex fluorescent *in situ* hybridization (mFISH) using VLT-
145 and ORF63-specific probes to simultaneously profile VLT, VLT-ORF63 and ORF63 RNA
146 expression in the same TG section. During lytic infection in HZ skin biopsies (**Fig. 2b,**
147 **lower panels**) and ARPE-19 cells (**Supplementary Fig. 2a**), VLT and ORF63 ISH signal
148 showed partial co-localization within the nucleus and largely divergent localization
149 within the cytoplasm of VZV-infected cells. Analysis of seven additional human TGs
150 (**Supplementary Table 3**) confirmed that VZV-infected neurons expressed nuclear VLT
151 RNA (**Fig. 2b, middle panels**) or co-expressed nuclear VLT and ORF63 RNA ISH signal (**Fig.**
152 **2b, upper panels**). Notably, both RNAs co-localized in the vast majority of neurons (i.e.

153 4-11 neurons/section, present in all 7 TGs analyzed). Only a small number of neurons, 4
154 neurons in total and in just 2 of 7 TGs analyzed, yielded staining that showed both RNAs
155 as distinct puncta (**Supplementary Fig. 2b**). Co-localization of VLT and ORF63 RNA ISH
156 signal during latency provides further support for the presence of VLT-ORF63 fusion
157 transcripts in human TG.

158 To further characterize and differentiate VLT, VLT-ORF63, and ORF63 transcripts in
159 human TGs, 5'-RACE analysis was performed on pooled poly(A)-selected RNA collected
160 from 3 TGs with detectable VLT-ORF63 transcripts (i.e. TG 2-4 in **Fig. 2a**). The VLT-specific
161 reverse primers (VLT_{exon4}R104361 and VLT_{exon5}R104799 in **Fig. 2c** and **Supplementary**
162 **Table 4**) identified two alternative TSS located 4 nt upstream and 21 nt downstream of
163 VLT exon 1 (**Fig. 2c, blue arrows**), and detected only the core VLT with no alternatively
164 spliced isoforms. The primers specifically binding to the ORF63 CDS (ORF63R622 and
165 ORF63R805 in **Fig. 2c** and **Supplementary Table 4**) identified only two VLT-ORF63
166 isoforms of with alternative splicing donor sites located in VLT exons 4 and 5, respectively
167 (**Fig. 2c**). Note that these VLT-ORF63 isoforms are identical to VLT-ORF63a and VLT-
168 ORF63b isoforms expressed during lytic VZV infection, except for the unique 5' ends that
169 discriminate latent from lytic VLT variants (**Fig. 1a**). Importantly, the TSS for all RNAs
170 containing ORF63 sequence in human TG were located close to VLT exon 1 and were part
171 of the VLT-ORF63 fusion transcript (**Fig. 2c, green arrows**), while no canonical ORF63
172 transcripts were detected. Collectively, these results implicate that most – if not all –
173 ORF63 RNA detected in latently VZV-infected human TG is attributed to VLT-ORF63
174 transcript expression.

175

176 ***Protein coding potential differs between VLT-ORF63 transcript isoforms.***

177 *In silico* translation of the two major VLT-ORF63 isoforms, VLT-ORF63a and VLT-ORF63b,
178 predicted novel proteins (**Fig. 3a** and **Supplementary Fig. 3**), whereas VLT-ORF63c (**Fig.**
179 **1a**) appears to encode solely canonical ORF63 protein (pORF63). VLT-ORF63a encodes a
180 putative in-frame fusion protein called pVLT-ORF63. The pVLT-ORF63 is predicted to 421
181 amino acids (aa) in length, comprising partial pVLT (aa 1-119) and the canonical pORF63
182 (278 aa) linked together by 24 aa polypeptide (GFVRFITRQRRVGFKKGKGYGPKD) encoded
183 within the partial 5'-UTR of ORF63 (**Fig. 3a**). The VLT-ORF63b isoform is predicted to
184 encode two separate proteins: complete pVLT (136 aa) and an N-terminally extended
185 336 aa pORF63 protein variant (pORF63-N+). pORF63-N+ includes an N-terminal 88 aa
186 polypeptide, the first 64 aa of which are translated from VLT exons 4 and 5, but out-
187 frame with pVLT, and the same 24 aa linker polypeptide of pVLT-ORF63 encoded from
188 the partial 5'-UTR of ORF63 (**Fig. 3a**).

189 The protein coding capabilities of the VLT-ORF63 isoforms were examined by
190 immunoblotting of ARPE-19 cells transfected with plasmids expressing VLT-ORF63a and
191 VLT-ORF63b, and ORF63 for comparison, as well as in lytically VZV-infected ARPE-19 cells
192 using antibodies raised against parts of pVLT and pORF63 (**Supplementary Fig. 4**). The
193 anti-pVLT antibody (Ab) was raised against the first 19 aa of pVLT⁷, being part of both
194 pVLT and pVLT-ORF63. The anti-pORF63 Ab was raised against whole pORF63⁷,
195 recognizing pVLT-ORF63, pORF63-N+ and pORF63. Translation of all predicted proteins
196 from each plasmid was confirmed in transfected ARPE-19 cells and both pVLT-ORF63 and

197 pORF63-N+ were readily detected in the context of lytic VZV infection (**Supplementary**
198 **Fig. 4**).

199 Next, we assayed the cellular localization of protein expression by
200 immunofluorescence. In transfected cells, pORF63 was detected in the nucleus and
201 particularly in the cytoplasm, whereas pVLT-ORF63 predominantly localized in the
202 nucleus (**Fig. 3b**). The same result was obtained with an antibody (anti-pVLT-ORF63 Ab)
203 specific for the 24 aa linker region present exclusively in the VLT-ORF63 fusion proteins.
204 Cells transfected with the VLT-ORF63b vector, encoding pVLT and fusion protein pORF63-
205 N+, resulted in nuclear and cytoplasmic pVLT but undetectable pORF63-N+ expression
206 (**Fig. 3b**). In lytically VZV-infected ARPE-19 cells, pVLT-ORF63 localized to the nucleus and
207 cytoplasm, as demonstrated by immunofluorescent staining with antibodies against
208 pVLT-ORF63, pVLT and pORF63 (**Fig. 3c**). Finally, we showed pVLT-ORF63 expression in HZ
209 skin biopsies that specifically localized in the cytoplasm of VZV-infected pORF63^{pos}
210 keratinocytes (**Fig. 3d**). Thus, pVLT-ORF63 and/or pORF63-N+ are expressed in VZV-
211 infected cells *in vitro* and *in vivo*.

212

213 ***Treatment with JNK activator promotes VLT-ORF63 transcription in latently VZV-***
214 ***infected sensory neurons.***

215 We next used our *in vitro* VZV sensory neuronal latency model¹² to examine transcription
216 patterns across the VLT and ORF63 loci by RT-qPCR during latency and reactivation.
217 Consistent with VZV latency in human TG, VLT was readily detectable in latently VZV-
218 infected HSN, while no other tested viral immediate early (IE), early (E) or late (L)

219 transcripts were detected (**Fig. 4a**). Notably, we detected neither ORF63 (CDS and 5'-
220 UTR) nor any of the VLT-ORF63 isoforms (**Fig. 4a**), whose absence was seen only in small
221 fraction of human TGs (**Fig. 2a** and reference⁷). 5'-RACE analysis of VLT and ORF63 loci
222 on RNA extracted from latently VZV-infected HSN confirmed expression of core VLT
223 isoform and usage of the two VLT TSS detected in human TG as well as a third TSS located
224 9 nt upstream of VLT exon 1 (**Fig. 2c, red arrows**), and the lytic VLT and VLT-ORF63
225 isoforms were not detected.

226 Similar to previously reported *in vitro* models for VZV latency using human
227 embryonic stem cell (hESC)-derived neurons^{17,18}, induction of complete virus
228 reactivation was relatively inefficient in our HSN model¹². Complete reactivation was
229 observed in 2 of 40 replicates, as demonstrated by the formation of infectious foci after
230 transferring the HSN onto and co-culturing with ARPE-19 cells (**Fig. 4b, upper panel**), and
231 associated with expression of all IE, E and L VZV transcripts tested in the HSN (**Fig. 4c,**
232 **black circle**). Although no infectious virus was detected in 38 replicates (**Fig. 4b, lower**
233 **panel**), low levels of multiple viral transcripts could be detected including VLT-ORF63a
234 indicative of exit from latency (**Fig. 4c, white circle**). These data indicate that VLT
235 expression is a hallmark of VZV latency in human sensory neurons *in vitro*, while VLT-
236 ORF63s are induced in response to reactivation stimuli.

237 Given the critical role of JNK activation as a trigger of HSV-1 lytic gene expression
238 during reactivation¹⁹ as well as the importance of the JNK signal in VZV reactivation²⁰,
239 we speculated that JNK activation may trigger VZV reactivation by inducing lytic gene
240 expression. Latently VZV-infected HSN were treated with the JNK activator anisomycin,

241 a compound that also inhibits protein synthesis. VZV reactivation, as measured by
242 transferring HSN onto ARPE-19 cells for infectious focus forming assay, could not be
243 detected. However, anisomycin treatment consistently increased VLT expression and
244 induced expression of VLT-ORF63a and VLT-ORF63b (**Fig. 4d**). By contrast, anisomycin
245 treatment induced only limited expression of ORF4 (1 of 3 replicates) or ORF61 (2 of 3
246 replicates), while no lytic VZV gene transcription was detected following mock treatment
247 (**Fig. 4e**). Thus, anisomycin-mediated JNK activation and/or inhibition of protein
248 synthesis selectively and consistently induces transcription of VLT and both VLT-ORF63
249 isoforms in parallel with or prior to induction of IE gene transcription.

250

251 ***Ectopic VLT-ORF63a expression induces broad viral gene expression in the latently VZV-***
252 ***infected sensory neuron model.***

253 The anisomycin-induced VLT-ORF63 transcription suggest that these transcripts directly,
254 or their encoded proteins, contribute to VZV reactivation. To investigate whether VLT-
255 ORF63a or VLT-ORF63b alone can induce VZV reactivation, latently VZV-infected HSN
256 were transduced with replication-incompetent lentivirus vectors encoding ORF63, the
257 latent VLT-ORF63a and VLT-ORF63b isoforms, or an empty vector control. Ectopic gene
258 transcription and translation was confirmed in all transduced cell cultures (**Fig. 5** and
259 **Supplementary Fig. 5**). Both in the empty vector and ORF63-transduced cells,
260 endogenous VLT was detected by RT-qPCR at comparable level (**Fig. 5a, b**). Sporadic IE
261 and E gene, but no L gene transcription was detected in ORF63- and VLT-ORF63b-
262 transduced cells (**Fig. 5b, c**). Notably, transcription of VZV IE, E and L genes was

263 consistently induced by ectopic VLT-ORF63a expression in latently VZV-infected HSN (**Fig.**
264 **5d**). Consistent with the absence of ORF62 transcription, which encodes the major viral
265 transactivator protein²¹, no infectious VZV was recovered from VLT-ORF63a-transduced
266 HSN cells. Given the differences in protein coding potential between the VLT isoforms
267 and compared to canonical ORF63 (**Fig. 3a**), the pVLT-ORF63 fusion protein is potentially
268 involved in the transition from latency to reactivation in our HSN VZV latency model.

269

270 **DISCUSSION**

271

272 VZV latency in human TG is characterized by detection of RNAs expressed from the VLT
273 and occasionally the ORF63 locus, where expression levels of both transcripts correlated
274 positively suggesting co-regulated transcription⁷. Here, we demonstrated that this
275 pattern is best explained by co-expression of VLT and two VLT-ORF63 fusion transcripts,
276 and not by expression of the canonical ORF63 transcripts independent of VLT. Further
277 characterization of the VLT-ORF63 isoforms, expressed during both lytic and latent VZV
278 infection, demonstrated that reactivation stimuli increase VLT and induce VLT-ORF63
279 expression in our *in vitro* VZV HSN latency model. Moreover, ectopic VLT-ORF63a
280 expression induced broad viral lytic gene transcription in latently VZV-infected HSN,
281 which is potentially mediated by the pVLT-ORF63 fusion protein.

282 Differential TSS usage of VLT between latently-VZV infected TGs and lytically VZV-
283 infected epithelial cells⁷ raises the question as to whether transcription of distinct VLT
284 isoforms depends on infection phase or cell type. Here, we demonstrated that

285 transcription of specific VLT and VLT-ORF63 isoforms is determined by the infection
286 phase rather than the cell type. While both lytic and latent transcript isoforms are
287 predicted to encode the same protein(s), the extended 5'-UTR in the lytic VLT and VLT-
288 ORF63 transcripts may confer new properties to the RNA. Alternative promoter usage of
289 viral genes between distinct but continuous infection phases has been implicated as a
290 switching mechanism of latency and lytic infection among herpesviruses²²⁻²⁴, and may
291 impact on the localization and/or function of both type of VZV transcripts at different
292 infection phases.

293 Transcriptional profiling of reactivating neurons in our *in vitro* HSN latency model
294 revealed the presence of multiple viral transcripts of all kinetic classes, including the VLT-
295 ORF63 RNAs. By contrast, when attempting to induce reactivation through anisomycin-
296 mediated activation of JNK signaling, previously shown to be required for VZV
297 reactivation and replication²⁰, only VLT-ORF63 transcription was consistently induced
298 along with higher expression levels of VLT. This provides a favorable explanation as to
299 how VZV initially reactivates from latency. As a counterpoint, we do note the limitations
300 imposed by using anisomycin to show a direct link between JNK signaling and complete
301 reactivation. Specifically anisomycin inhibits protein synthesis and just 1 hr exposure to
302 anisomycin induces a terminal decline of neuronal cultures with death occurring within
303 14 days of treatment, regardless of whether cells were latently VZV-infected or not.
304 Hence, further studies are needed to delineate the mechanisms by which JNK signaling
305 regulates VZV gene expression and reactivation in latently VZV-infected HSN.

306 The VLT-ORF63a, but not VLT-ORF63b isoform induced broad lytic viral gene
307 transcription in latently VZV-infected HSN cultures. While these two isoforms differ only
308 by the partial presence/absence of VLT core exon 5, only VLT-ORF63a encodes for the
309 pVLT-ORF63, suggesting that the encoded protein and not the transcript itself regulates
310 transcription of VZV genes. Canonical pORF63 has been reported to both positively and
311 negatively affect VZV gene transcription during lytic infection^{25,26}, depending on its
312 phosphorylation status and cell type analyzed²⁷. Here, we showed that pORF63 induces
313 expression of IE gene ORF61 encoding a promiscuous transactivator protein²⁸ and the E
314 gene ORF16, but not any of the other analyzed VZV IE, E or L genes in our *in vitro* HSN
315 latency model. By contrast, pVLT-ORF63 induced expression of multiple VZV genes of all
316 kinetic classes. Overall, the data suggest a key role for pVLT-ORF63 in the initiation of
317 VZV reactivation and emphasize the importance of uncharacterized cellular factors
318 and/or other viral factors (e.g. expression of the major viral transcriptional activator
319 pORF62, which is consistently absent in VLT-ORF63a transduction) that are required for
320 complete VZV reactivation for future studies.

321 HSV reactivation has been proposed to be consisted with two distinct but
322 continuous waves of lytic gene transcription. The first wave designated as animation²⁹
323 or Phase I^{30,31} is characterized by generalized viral gene derepression^{30,32}, in contrast the
324 second wave (Phase II) is identical to the cascade observed during acute infection.
325 Transition from latency to Phase I and Phase I to Phase II might work as checkpoints
326 whether to lead complete reactivation or to halt reactivation and re-enter latency³⁰.
327 While we do not know whether animation/Phase I occurs during VZV reactivation, broad

328 transcription of viral genes of all kinetic classes was induced by reactivation stimuli,
329 occasionally leading to complete reactivation in our *in vitro* HSN latency model. Notably,
330 our data demonstrates that broad VZV transcription is initiated by VLT-ORF63
331 transcription/pVLT-ORF63 translation, unlike Phase I of HSV reactivation for which no
332 viral initiator has been proposed to drive HSV gene expression. Thus, there might be
333 critical differences between the mechanism(s) governing HSV and VZV latency and
334 reactivation.

335 Taken together, our discovery of the VLT-ORF63 fusion transcripts in VZV-infected
336 human TG and the ability of the encoded pVLT-ORF63 fusion protein to act as an initiator
337 of viral gene expression during reactivation in our *in vitro* HSN latency model provides
338 critical new insights into how VZV latency and reactivation are governed. Further studies
339 using the HSN VZV latency model, combined with careful analyses of human ganglia,
340 provides a new platform to dissect the cellular and viral molecular mechanisms
341 controlling VZV latency and reactivation. VZV is the only human herpesvirus for which
342 vaccines are licensed. However, the live-attenuated varicella vaccine establishes latency
343 and may reactivate to cause disease, while adjuvanted recombinant zoster vaccine is
344 highly effective against HZ prevention but not suited for childhood varicella vaccination.
345 The discovery of VLT-ORF63 and its role in reactivation provides new insight that will
346 inform efforts to improve varicella vaccines.

347

348 **METHODS**

349

350 ***Human clinical specimens.***

351 Human TG specimens were obtained (**Supplementary Tables 1 and 2**) from the
352 Netherlands Brain Bank (Netherlands Institute for Neuroscience; Amsterdam, the
353 Netherlands). All donors had provided written informed consent for brain autopsy and
354 the use of material and clinical information for research purposes. All study procedures
355 were performed in compliance with relevant laws in The Netherlands and Japan,
356 institutional guidelines approved by the local ethical committee (VU University Medical
357 Center, Amsterdam, project number 2009/148, and Kobe University, Kobe, project
358 number 170107) and in accordance with the ethical standards of the Declaration of
359 Helsinki. TG biopsies were either formalin-fixed and paraffin-embedded (FFPE) for *in situ*
360 analysis or snap-frozen in liquid nitrogen and stored at -80°C for nucleic acid extraction.
361 FFPE skin punch biopsies of one healthy control subject and two herpes zoster skin
362 lesions were obtained for diagnostic purposes. According to the institutional “Opt-Out”
363 system (Erasmus MC, Rotterdam, the Netherlands), which is defined by the National
364 “Code of Good Conduct” [Dutch: Code Goed Gebruik, May 2011], the surplus human
365 herpes zoster FFPE tissues were available for the current study.

366

367 ***Cells.***

368 Human iPSC-derived sensory neuron (HSN) progenitors (Axol Bioscience) were plated on
369 a 24-well plate (1×10^5 cells/well), CELLview Slide (Greiner Bio-One) (1×10^4 cells/well)

370 or a microfluidic platform (7.5×10^4 cells/sector) in Neuronal Plating-XF Medium (Axol
371 Bioscience). Fabrication of a microfluidic platform was previously described³³. Prior to
372 plating the HSN progenitors, a plate, slide or microfluidic platform was coated with poly-
373 L-ornithine (Sigma-Aldrich) (20 $\mu\text{g}/\text{mL}$) or poly-D-lysine (Sigma-Aldrich) (200 $\mu\text{g}/\text{mL}$) in
374 molecular grade water at room temperature overnight, washed with distilled water
375 twice and coated with Matrigel (Corning) (1 $\mu\text{g}/\text{mL}$) in Knockout DMEM/F-12 medium
376 (Thermo Fisher Scientific) for 2 hr at room temperature following overnight incubation
377 at 37°C in a humidified 5% CO₂ incubator. At 1 day after plating, the medium was replaced
378 to the complete maintenance medium consisted with Neurobasal Plus Medium, B-27
379 Plus Supplement (2% [vol/vol]), N2 Supplement (1% [vol/vol]), GlutaMAX-I (2 mM)
380 (Thermo Fisher Scientific), ascorbic acid (200 μM ; Sigma-Aldrich), GDNF (25 ng/mL), NGF
381 (25 ng/mL), BDNF (10 ng/mL) and NT-3 (10 ng/mL) (Peprotech) for sensory neuronal
382 maturation. Two days after the plating the HSN progenitors, cells were treated with the
383 complete maintenance medium with mitomycin C (2.5 $\mu\text{g}/\text{mL}$; Nacalai Tesque, Inc.) for
384 2 hr to eliminate proliferating cells, washed with the complete medium twice and culture
385 in the complete maintenance medium at least 7 weeks with replacing half the volume
386 of culture with the fresh medium every 4 days. During maturation in the microfluidic
387 platform, culture medium level in the axonal compartment was kept higher than that in
388 the somal compartment to prevent cell migration to the axonal compartment. The
389 maturation of sensory neurons was characterized previously¹². Human retinal
390 pigmented epithelium ARPE-19 cells (American Type Culture Collection [ATCC] CRL-
391 2302) were maintained in DMEM/F-12+GlutaMAX-I (Thermo Fisher Scientific)

392 supplemented with heat-inactivated 8% FBS (foetal bovine serum; Sigma-Aldrich).
393 Human embryonic kidney (HEK) 293T cells (ATCC CRL-3216) were cultured in
394 DMEM+GlutaMAX-I (Thermo Fisher Scientific) supplemented with heat-inactivated 8%
395 FBS.

396

397 **VZV infections.**

398 VZV strain pOka (parental Oka) was maintained in and the cell-free virus was prepared
399 from ARPE-19 cells as described previously for human embryonic lung fibroblast MRC-5
400 cells³⁴. For lytic infection in ARPE-19 cells, cells were plated on 12-well plate at a density
401 of 1×10^5 cells/well 2 days before infection, infected with the cell-free virus (3×10^3 pfu
402 [plaque-forming unit] to 1 well) for 1 hr in 500 μ L medium, washed with the medium
403 twice and cultured for 4 days. For lytic infection for HSN, cells were matured as
404 described above, infected with the cell-free virus (4×10^3 pfu to 1 well) at 52 days after
405 maturation for 2 hrs in 400 μ L medium, washed with the medium twice, treated with
406 low pH buffer (40 mM sodium citrate, 10 mM potassium chloride, 135 mM sodium
407 chloride [pH 3.2]) for 30 seconds (sec), washed with the medium once and cultured for
408 2 weeks to obtain efficient lytic infection as described¹².

409 For *in vitro* VZV latency, the method was established previously for human
410 embryonic stem cell-derived neurons¹⁸ and applied for HSN¹². Briefly, HSN were
411 matured on a microfluidic platform for 54 days and infected via axonal chamber with
412 10 μ L of the cell-free virus (4×10^4 pfu/mL titrated on ARPE-19 cells) in 20 μ L total volume.
413 After 2 hr infection, inoculum was removed, and axons were treated with the low pH

414 buffer for 30 sec, washed with the medium and cultured for 2 weeks. To reactivate VZV
415 from sensory neuronal latency, GDNF, NGF, BDNF and NT-3 were depleted from and
416 anti-NGF polyclonal antibody (50 µg/mL) was added to the complete maintenance
417 medium, and cultures were maintained for 2 weeks. For chemical induced reactivation,
418 latently VZV-infected HSN was treated with JNK activator, anisomycin (20 µg/mL) or
419 solvent control (DMSO [dimethyl sulfoxide]) for 1 hr from both axonal and somal
420 compartment, washed with the medium twice and cultured in the complete
421 maintenance medium without GDNF, NGF, BDNF and NT-3 for 1 week. For VZV gene
422 transduction, VZV-latently infected HSN was transduced by lentivirus vector for 2 hr
423 from somal compartment with mixing by pipetting at 30 minutes (min) and 1.5 hr after
424 transduction, cultured overnight and replaced the medium in both somal and axonal
425 compartment with the fresh complete maintenance medium without GDNF, NGF, BDNF
426 and NT-3 for 2 weeks. The complete reactivation was confirmed by the formation of
427 infectious foci after transferring the HSN onto and co-culturing with ARPE-19 cells for 7
428 days as described below.

429

430 ***DNA, RNA and cDNA.***

431 DNA and RNA were isolated from human TGs (n = 4) (**Supplementary Table 2**) as
432 described previously⁷. DNA and RNA from VZV-infected ARPE-19 cells or HSN were
433 isolated as described previously⁷ with slight modifications using the FavorPrep
434 Blood/Cultured Cell Total RNA Mini Kit (FAVORGEN BIOTECH) in combination with the
435 NucleoSpin RNA/DNA buffer set (Macherey-Nagel). DNA was first eluted from the

436 column in 80 μ L DNA elution buffer, the column was treated with recombinant DNase I
437 (20 units/100 μ L; Roche Diagnostics) for 30 min at 37°C and RNA was eluted in 50 μ L
438 nuclease free water. RNA was directly treated with Baseline-ZERO DNase (2.5 units/50
439 μ L; Epicentre) for 30 min at 37°C (all the RNA), and further purified by Dynabeads mRNA
440 purification kit (Thermo Fisher Scientific) (TG RNA) or enriched by Agencourt RNAClean
441 XP (Beckman Coulter) (*in vitro* latency RNA). cDNA was synthesized with 12 μ L of RNA
442 and anchored oligo(dT)₁₈ primer in a 20 μ L reaction using the Transcriptor First Strand
443 cDNA synthesis kit at 55°C for 30 min for reverse transcriptase reaction (Roche
444 Diagnostics).

445

446 ***Quantitative PCR and 5'-RACE analysis.***

447 DNA or cDNAs were subjected to quantitative PCR (qPCR) using KOD SYBR qPCR Mix
448 (TOYOBO) in the StepOnePlus Real-time PCR system (Thermo Fisher Scientific) (1 μ L of
449 DNA or cDNA per 10 μ L reaction in duplicate). All the primer sets used for qPCR
450 (**Supplementary Table 1**) were first confirmed for the amplification rate (98-100%) using
451 10-10⁶ copies (10-fold dilution) of pOka-BAC genome or VLT-ORF63 plasmids and the lack
452 of non-specific amplification using water. Due to the partially antisense nature of VLT via
453 exon 3 and exon 4 against ORF61, a primer pair of exons 3 and 4 detected both VLT and
454 ORF61, thus a primer pair of exons 2 and 4 was used for lytic infection instead a primer
455 pair of exons 3 and 4 used for *in vivo* and *in vitro* latency in which ORF61 is absent. The
456 qPCR program is as follows; 95°C for 2 min (1 cycle), 95°C for 10 sec and 60°C 15 sec (40
457 cycles), and 60 to 95°C for a dissociation curve analysis to discriminate non-specific signal

458 if any. Data is presented as relative transcription level of VZV gene to cellular beta-actin
459 defined as $2^{-(\text{Ct-value VZV gene} - \text{Ct-value beta-actin})}$.

460 5'-RACE analysis was performed using SMARTer RACE 5'/3' kit and In-Fusion HD
461 Cloning kit according to the manufacturer's instructions with slight modifications
462 (Clontech). 5'-RACE ready cDNA was synthesized from purified mRNA (TG) or total RNA
463 (HSN) with SMARTerIIA Oligonucleotide and 5'-RACE CDS Primer A. KOD FX Neo PCR
464 system (TOYOBO) was used for 5'-RACE PCR and the program was 1 cycle of 94°C for 2
465 min and 30 cycles of 95°C for 10 sec and 68°C for 1 min. Initial PCR was performed by
466 Universal Primer Mix (a mixture of Universal Primer Long and Universal Primer Short)
467 and InFusionVLTxon5R104799 for VLT or InFusionORF63R805 for VLT-ORF63 fusions.
468 Nested PCR, if necessary, was carried out using Universal Primer Long and
469 InFusionVLTxon4R10361 for VLT or InFusionORF63R622 for VLT-ORF63 fusions. The 5'-
470 RACE PCR products were cloned into linearized pRACE cloning vector and sequenced by
471 M13forward or M13reverse on the ABI Prism 3130 XL Genetic Analyzer using the BigDye
472 v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific). All the primers used for 5'-RACE
473 analysis are listed in **Supplementary Table 4**.

474

475 ***Direct RNA sequencing and cDNA sequencing on nanopore array.***

476 Direct RNA sequencing libraries were generated from 117 - 153 ng of poly(A) RNA,
477 isolated using Dynabeads mRNA purification kit. Isolated poly(A) RNA was subsequently
478 spiked with 0.5 µl of a synthetic Enolase 2 (ENO2) calibration RNA (Oxford Nanopore
479 Technologies Ltd.) and sequenced on a MinION Mk1b with R9 flow cells (Oxford

480 Nanopore Technologies Ltd.) for 40 hr, as previously described¹⁴. cDNA sequencing
481 libraries were generated from 1 ng of poly(A) RNA, isolated using Dynabeads mRNA
482 purification kit using cDNA-PCR Sequencing kit (SQK-PCS109) (Oxford Nanopore
483 Technologies Ltd.) and sequenced on a MinION Mk1b with R9 flow cells for 40 hr.
484 Following basecalling with Albacore, only the reads in the pass folder were used. Error-
485 correction was performed using proovread as described previously¹⁴. Nanopore read
486 data were aligned to the VZV strain dumas genome (X04370.1) using MiniMap2³⁵ and
487 parsed using SAMtools³⁶ and BEDTools³⁷.

488

489 ***Multiplex fluorescent RNA in situ hybridization in human cadaveric TG.***

490 FFPE latently VZV-infected human TG (n = 7) (**Supplementary Table 3**), human zoster skin
491 biopsies and lytically VZV-infected ARPE-19 cells were analyzed by multiplex fluorescent
492 *in situ* hybridization (mFISH) using the RNAScope Multiplex Fluorescent Reagent Kit v2
493 (Advanced Cell Diagnostics) according to the manufacturer's instructions. Briefly,
494 deparaffinized 5 µm-thick tissue sections were incubated with probes directed to ORF63
495 and VLT exons 2 – 5. RNA integrity and mFISH specificity were demonstrated by staining
496 TGs for ubiquitously expressed cytoplasmic transcript ubiquitin C, nuclear transcript
497 MALAT1 (positive controls) and bacterial gene DAPB (negative control probe)
498 (**Supplementary Fig. 2C**). Probes were designed by Advanced Cell Diagnostics. Sections
499 were mounted with Prolong Diamond antifade mounting medium and confocal
500 microscopic analysis was performed on a Zeiss LSM 710 confocal microscope, as
501 described³⁸.

502

503 ***Replication incompetent lentivirus vectors.***

504 VZV genes, ORF63, VLT-ORF63a or VLT-ORF63b were amplified by PCR of cDNA from VZV
505 pOka-infected ARPE-19 cells. The PCR product was digested with Sall restriction enzyme
506 and cloned into CS-CA-MCS plasmid (Riken BioResource Research Center) via Sall site
507 (ORF63) or directly cloned into linearized CS-CA-MCS (VLT-ORF63a and VLT-ORF63b)
508 using In-Fusion HD Cloning kit according to the manufacturer's instruction (Clontech).
509 The primer sets used for cDNA cloning into the CS-CA-MCS plasmid are listed in
510 **Supplementary Table 4**. HEK293T cells (4×10^6 cells) were plated onto a 10 cm dish,
511 transfected with CS-CA-MCS or CS-CA-VZV (20 μ g) and packaging plasmids, pCAG-HIVgp
512 (5 μ g) and pCMV-VSV-G-RSV-Rev (5 μ g) (Riken BioResource Research Center) using
513 PEI_{max} solution (60 μ L) (Polysciences) prepared in KnockoutDMEM/F-12 (500 μ L) at 6 hr
514 post plating and cultured overnight in 8% CO₂ incubator in 10 mL DMEM+GlutaMAX-I
515 with heat-inactivated 8% FBS. Whole culture medium was change with the fresh medium
516 at 16 hr after transfection and cells were cultured for another 48 hr. Supernatant (20 mL)
517 were filtrated through 0.45 μ m syringe filter (Pall), mixed with 5 mL of PEG6000 (50%
518 [wt/vol] in PBS), 1.7 mL of 5 M NaCl and 2.6 mL of PBS, and rotated in a 50 mL conical
519 tube at 4°C at least 8 hr. After centrifugation at 7,000 x g for 10 min, supernatant was
520 removed, pellet was resuspended in 300 μ L of KnockoutDMEM/F-12, aliquoted out in 4
521 tubes and stored at -80°C until use. Quantity of each replication incompetent lentivirus
522 vector was measured by qPCR of cDNA synthesized with random hexamer from genomic
523 RNA packaged in enriched pseudo virion using the primer set, CSCA1831F and

524 CSCA1969R (**Supplementary Table 1**) detecting upstream promoter region in CS-CA-MSC
525 plasmid and equal amount of virus were used for transductions.

526

527 ***Antibodies.***

528 Chicken polyclonal antibody (pAb) against 24 aa linker peptide
529 (GFVRFITRQRRVGFKKGKGGYGPKE) of pVLT-ORF63 fusion protein, anti-pVLT-ORF63 pAb
530 was generated and purified through an immunogen conjugated peptide column (Cosmo
531 Bio). Rabbit anti-pVLT pAb, rabbit anti-pORF63 pAb⁷, mouse anti-pORF63 monoclonal
532 antibody (mAb)(clone VZ63.08)³⁹, and mouse anti-glycoprotein E (gE) mAb⁴⁰ were
533 described previously. Anti-alpha tubulin mAb (clone B-5-1-2; Sigma-Aldrich) and sheep
534 anti-NGF pAb (EMD Millipore) are commercially available. Alexa Fluor 488- or Alexa
535 Fluor 647-conjugated donkey anti-mouse IgG, Alexa Fluor 594-conjugated donkey anti-
536 rabbit IgG (Thermo Fisher Scientific) and Alexa Fluor 488-conjugated donkey anti-
537 chicken IgY (Jackson ImmunoResearch Laboratories) were used for secondary Abs for
538 indirect immunofluorescent assay. Anti-mouse IgG HRP-linked Whole Ab Sheep or anti-
539 rabbit IgG HRP-linked Whole Ab Donkey (GE Healthcare Bio-Sciences) were used as
540 secondary Abs for immunoblotting.

541

542 ***Immunofluorescent staining, confocal microscopy, infectious foci staining and***
543 ***immunoblotting.***

544 Cells on CELLview slide were fixed with 4% (vol/vol) paraformaldehyde (PFA)/PBS
545 (Nacalai Tesque, Inc.) at room temperature for 20 min, permeabilized with 0.1% Triton

546 X-100/4% PFA/PBS at room temperature for 20 min, and incubated with human Fc
547 receptor blocking solution (5% FBS/PBS containing 10% of Clear Back [MBL]) at room
548 temperature for 1 hr. Cells were stained with the primary Abs diluted in a solution (5%
549 FBS/PBS) overnight at 4°C (1:100 for anti-pVLT pAb, anti-pVLT-ORF63 pAb and anti-
550 pORF63 mAb, 1:300 for all Abs against neuronal markers, 1:500 for anti-pORF63 pAb),
551 washed with 0.1% Tween 20/PBS (PBS-T) for 5 min 3 times, stained with the secondary
552 Abs (1:300) diluted in 5% FBS/PBS at room temperature for 1 hr, washed with PBS-T for
553 5 min 3 times, covered with VECTASHIELD Vibrance Antifade Mounting Medium with
554 DAPI (Vector Laboratories) and imaged by an FV1000D confocal microscopy (Olympus).

555 Deparaffinized and rehydrated 5 µm FFPE sections of human herpes zoster skin
556 lesions and healthy control skin were subjected to heat-induced antigen retrieval with
557 citrate buffer (pH=6.0), blocked and incubated with mouse anti-VZV pORF63 (1:1,500
558 dilution; kindly provided by Dr. Sadzot-Delvaux; Liege, Belgium⁴¹), chicken anti-pVLT-
559 ORF63 (1:100 dilution) overnight at 4°C. Sections were subsequently incubated with
560 Alexa Fluor 488- and Alexa Fluor 594-conjugated goat-anti-mouse and goat-anti-chicken
561 secondary antibodies (all 1:250 dilution) and sections were mounted with Prolong
562 Diamond antifade mounting medium with DAPI. Confocal microscopic analysis was
563 performed as described³⁸.

564 To visualize infectious foci on ARPE-19 cells, cells were fixed with 4% PFA/PBS,
565 stained with anti-gE mAb (1 : 10 dilution in PBS), followed by anti-mouse IgG HRP-linked
566 whole Ab sheep (1:5,000 dilution in PBS), and reacted with 3, 3', 5, 5'-
567 tetramethylbenzidine-H peroxidase substrate (Moss, Inc.).

568 Cells were incubated in RIPA lysis buffer (0.01 M Tris-HCl [pH 7.4], 0.15 M NaCl,
569 1% sodium deoxycholate, 1% Nonidet P-40 and 0.1% SDS) on ice for 15 min, sonicated
570 in a water bath for 10 min, centrifuged at 20,000 x g for 15 min. Supernatant was boiled
571 with LDS Sample Buffer (4X) and Sample Reducing Agent (10X) at 100°C for 5 min
572 (Thermo Fisher Scientific). Proteins were separated on 4-12% Bis-Tris Plus Gel in MES
573 SDS Running Buffer (200 V, 25 min), transferred onto PVDF membrane (0.2 µm) using
574 Mini Blot Module (20V, 1 hr) in Bolt Transfer Buffer containing 10% methanol and 0.1%
575 Bolt Antioxidant (Thermo Fisher Scientific). The membrane was blocked in a blocking
576 buffer (5% [wt/vol] skimmed milk/0.1% Tween 20/PBS) at room temperature for 1 hr,
577 stained with primary Abs diluted in the blocking buffer (1:1,000 for anti-pVLT pAb,
578 1:6,000 for anti-pORF63 pAb and 1:10,000 for anti-alpha tubulin mAb) overnight at 4°C,
579 washed with PBS-T for 5 min 3 times, stained with the secondary Abs diluted in the
580 blocking buffer (1:3,000) at room temperature for 30 min, and washed with PBS-T for 5
581 min 3 times and PBS briefly once. Signals were visualized by Chemi-Lumi One Super
582 Nacalai Tesque, Inc.) and captured using LAS4000mini (GE Healthcare Bio-Sciences). A
583 membrane stained with anti-pVLT pAb was stripped by WB Stripping Solution Strong in
584 accordance with the manufacturer's manual (Nacalai Tesque, Inc.) and reprobed with
585 anti-alpha-tubulin mAb.

586

587 **Data Availability**

588 Basecalled fast5 nanopore dRNA- and cDNA-Seq datasets generated as part of this study
589 can be downloaded from the European Nucleotide Archive (ENA) under the following

590 study accession: PRJEB36978. The authors declare that all other data supporting the
591 findings of this study are available within the article and its Supplementary Information
592 files, or are available from the authors upon request.

593

594 **Acknowledgements**

595 We are grateful to Yasuko Mori for use of laboratory equipment, Angus C. Wilson and
596 Ian Mohr for critical reading of the manuscript. This work was supported by the Takeda
597 Science Foundation, Daiichi Sankyo Foundation of Life Science, Japan Society for the
598 Promotion of Science (JSPS KAKENHI JP17K008858, JP16H06429 and JP16K21723) and
599 the Ministry of Education, Culture, Sports, Science and Technology (MEXT KAKENHI
600 JP17H05816) (T. S.). A. V. is supported by the NIH NINDS (R21NS107991). J. B. receives
601 funding from the UCL/UCLH NIHR Biomedical Research Centre. S. J. and T. L. R. are
602 supported by “Strengthening the capacity of CerVirVac for research in virus immunology
603 and vaccinology”, grant no. KK.01.1.1.01.0006, awarded to the Scientific Centre of
604 Excellence for Virus Immunology and Vaccines and co-financed by the European
605 Regional Development Fund. The funders had no role in study design, data collection,
606 and interpretation, or in the decision to submit the work for publication.

607

608

609 **REFERENCES**

610

611 1. Cohen, J. I. in *Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis*
612 (eds. Arvin, A. M. et al.) (Cambridge University Press, 2007).

613 2. Gershon, M. & Gershon, A. Varicella-Zoster Virus and the Enteric Nervous System.
614 *J INFECT DIS* **218**, S113–S119 (2018).

615 3. Gershon, A. A. *et al.* Varicella zoster virus infection. *Nat. Rev. Dis. Primers* **1**, 15016
616 (2015).

617 4. Abendroth, A. & Arvin, A. M. in *Human Herpesviruses: Biology, Therapy, and*
618 *Immunoprophylaxis* (eds. Arvin, A. M. et al.) (Cambridge University Press, 2007).

619 5. Tseng, H. F. *et al.* The epidemiology of herpes zoster in immunocompetent,
620 unvaccinated adults ≥ 50 years old: incidence, complications, hospitalization,
621 mortality, and recurrence. *J INFECT DIS* **57**, 1 (2019).

622 6. Chen, S. Y. *et al.* Incidence of herpes zoster in patients with altered immune
623 function. *Infection* **42**, 325–334 (2014).

624 7. Depledge, D. P. *et al.* A spliced latency-associated VZV transcript maps antisense
625 to the viral transactivator gene 61. *Nature Communications* **9**, 1167 (2018).

626 8. Depledge, D. P., Sadaoka, T. & Ouwendijk, W. J. D. Molecular Aspects of Varicella-
627 Zoster Virus Latency. *Viruses* **10**, 349 (2018).

628 9. Ouwendijk, W. J. D. *et al.* Restricted varicella-zoster virus transcription in human
629 trigeminal Ganglia obtained soon after death. *Journal of Virology* **86**, 10203–
630 10206 (2012).

- 631 10. Prazsák, I. *et al.* Long-read sequencing uncovers a complex transcriptome
632 topology in varicella zoster virus. *BMC Genomics* **19**, 873 (2018).
- 633 11. Garalde, D. R. *et al.* Highly parallel direct RNA sequencing on an array of
634 nanopores. *Nat. Methods* **15**, 201–206 (2018).
- 635 12. Sadaoka, T. *et al.* Human stem cell derived sensory neurons are positioned to
636 support varicella zoster virus latency. *bioRxiv* 1–35 (2020).
637 doi:10.1101/2020.01.24.919290
- 638 13. Depledge, D. P., Mohr, I. & Wilson, A. C. Going the Distance: Optimizing RNA-Seq
639 Strategies for Transcriptomic Analysis of Complex Viral Genomes. *Journal of*
640 *Virology* **93**, 860 (2019).
- 641 14. Depledge, D. P. *et al.* Direct RNA sequencing on nanopore arrays redefines the
642 transcriptional complexity of a viral pathogen. *Nature Communications* **10**, 754
643 (2019).
- 644 15. Kinchington, P. R., Vergnes, J. P., Defechereux, P., Piette, J. & Turse, S. E.
645 Transcriptional mapping of the varicella-zoster virus regulatory genes encoding
646 open reading frames 4 and 63. *Journal of Virology* **68**, 3570–3581 (1994).
- 647 16. Kost, R. G., Kupinsky, H. & Straus, S. E. Varicella-zoster virus gene 63: transcript
648 mapping and regulatory activity. *Virology* **209**, 218–224 (1995).
- 649 17. Markus, A., Lebenthal-Loinger, I., Yang, I. H., Kinchington, P. R. & Goldstein, R. S.
650 An In Vitro Model of Latency and Reactivation of Varicella Zoster Virus in Human
651 Stem Cell-Derived Neurons. *PLoS Pathog* **11**, e1004885 (2015).
- 652 18. Sadaoka, T. *et al.* In vitro system using human neurons demonstrates that

- 653 varicella-zoster vaccine virus is impaired for reactivation, but not latency. *Proc*
654 *Natl Acad Sci USA* **113**, E2403–12 (2016).
- 655 19. Cliffe, A. R. *et al.* Neuronal Stress Pathway Mediating a Histone Methyl/Phospho
656 Switch Is Required for Herpes Simplex Virus Reactivation. *Cell Host Microbe* **18**,
657 649–658 (2015).
- 658 20. Kurapati, S. *et al.* Role of the JNK Pathway in Varicella-Zoster Virus Lytic Infection
659 and Reactivation. *Journal of Virology* **91**, e00640–17 (2017).
- 660 21. Inchauspe, G., Nagpal, S. & Ostrove, J. M. Mapping of two varicella-zoster virus-
661 encoded genes that activate the expression of viral early and late genes. *Virology*
662 **173**, 700–709 (1989).
- 663 22. Strassheim, S. *et al.* Oncogenic Marek's disease herpesvirus encodes an isoform
664 of the conserved regulatory immediate early protein ICP27 generated by
665 alternative promoter usage. *J Gen Virol* **97**, 2399–2410 (2016).
- 666 23. Wakeman, B. S., Izumiya, Y. & Speck, S. H. Identification of Novel Kaposi's
667 Sarcoma-Associated Herpesvirus Orf50 Transcripts: Discovery of New RTA
668 Isoforms with Variable Transactivation Potential. *Journal of Virology* **91**, (2017).
- 669 24. Collins-McMillen, D. *et al.* Alternative promoters drive human cytomegalovirus
670 reactivation from latency. *Proc Natl Acad Sci USA* **116**, 17492–17497 (2019).
- 671 25. Jackers, P. *et al.* Characterization of regulatory functions of the varicella-zoster
672 virus gene 63-encoded protein. *Journal of Virology* **66**, 3899–3903 (1992).
- 673 26. Lynch, J. M., Kenyon, T. K., Grose, C., Hay, J. & Ruyechan, W. T. Physical and
674 functional interaction between the varicella zoster virus IE63 and IE62 proteins.

- 675 *Virology* **302**, 71–82 (2002).
- 676 27. Bontems, S. *et al.* Phosphorylation of varicella-zoster virus IE63 protein by casein
677 kinases influences its cellular localization and gene regulation activity. *J Biol Chem*
678 **277**, 21050–21060 (2002).
- 679 28. Moriuchi, H., Moriuchi, M., Straus, S. E. & Cohen, J. I. Varicella-zoster virus (VZV)
680 open reading frame 61 protein transactivates VZV gene promoters and enhances
681 the infectivity of VZV DNA. *Journal of Virology* **67**, 4290–4295 (1993).
- 682 29. Penkert, R. R. & Kalejta, R. F. Tegument protein control of latent herpesvirus
683 establishment and animation. *Herpesviridae* **2**, 3 (2011).
- 684 30. Kim, J. Y., Mandarino, A., Chao, M. V., Mohr, I. & Wilson, A. C. Transient Reversal
685 of Episome Silencing Precedes VP16-Dependent Transcription during
686 Reactivation of Latent HSV-1 in Neurons. *PLoS Pathog* **8**, e1002540 (2012).
- 687 31. Wilson, A. C. & Mohr, I. A cultured affair: HSV latency and reactivation in neurons.
688 *TRENDS in Microbiology* **20**, 604–611 (2012).
- 689 32. Du, T., Zhou, G. & Roizman, B. HSV-1 gene expression from reactivated ganglia is
690 disordered and concurrent with suppression of latency-associated transcript and
691 miRNAs. *Proc Natl Acad Sci USA* **108**, 18820–18824 (2011).
- 692 33. Tegenge, M. A. *et al.* Curcumin protects axons from degeneration in the setting
693 of local neuroinflammation. *Exp. Neurol.* **253**, 102–110 (2014).
- 694 34. Sadaoka, T. *et al.* Varicella-Zoster Virus ORF49 Functions in the Efficient
695 Production of Progeny Virus through Its Interaction with Essential Tegument
696 Protein ORF44. *Journal of Virology* **88**, 188–201 (2014).

- 697 35. Li, H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics* **34**,
698 3094–3100 (2018).
- 699 36. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics*
700 **25**, 2078–2079 (2009).
- 701 37. Quinlan, A. R. BEDTools: The Swiss-Army Tool for Genome Feature Analysis. *Curr*
702 *Protoc Bioinformatics* **47**, 11.12.1–34 (2014).
- 703 38. Ouwendijk, W. J. D. *et al.* T-Cell tropism of simian varicella virus during primary
704 infection. *PLoS Pathog* **9**, e1003368 (2013).
- 705 39. Lenac Roviš, T. *et al.* Comprehensive analysis of varicella-zoster virus proteins
706 using a new monoclonal antibody collection. *Journal of Virology* **87**, 6943–6954
707 (2013).
- 708 40. Okuno, T., Yamanishi, K., Shiraki, K. & Takahashi, M. Synthesis and processing of
709 glycoproteins of Varicella-Zoster virus (VZV) as studied with monoclonal
710 antibodies to VZV antigens. *Virology* **129**, 357–368 (1983).
- 711 41. Kennedy, P. G., Grinfeld, E., Bontems, S. & Sadzot-Delvaux, C. Varicella-Zoster
712 virus gene expression in latently infected rat dorsal root ganglia. *Virology* **289**,
713 218–223 (2001).
- 714

715 **FIGURE LEGENDS**

716

717 **Figure 1. Transcription profile across the VLT and ORF63 loci during lytic VZV infection**

718 **of human sensory neurons and epithelial cells. a** Coverage plots denoting dRNA-Seq

719 (ARPE-19 epithelial cells, dark blue) and cDNA-seq (HSN, light blue) data aligned to the

720 top strand of the VZV genome. dRNA-Seq data is representative of two independently

721 sequenced biological replicates with RNA was extracted from lytically VZV-infected

722 ARPE-19 cells at 4 days post-infection (4 dpi). cDNA-Seq data was generated from a pool

723 of biological replicates collected from lytically-infected HSN at 14 dpi. Schematics of the

724 major transcripts from VLT and ORF63 loci are shown in following colors: lytic VLT

725 isoform (red), canonical ORF63 (light green), lytic VLT-ORF63 isoforms (purple) and

726 latent VLT isoform (orange). **b** Analysis of VLT, ORF63 and VLT-ORF63 isoform expression

727 by RT-qPCR analysis using the same two independent experiments in ARPE-19 cells

728 (black) and HSN (white) for long read sequencing. Data represent mean \pm SEM (standard

729 error of mean). The primer location used for RT-qPCR analysis detecting transcripts from

730 VLT to ORF63 loci are depicted in Supplementary Figure 1.

731

732 **Figure 2. Transcription profile across the VLT and ORF63 loci in latently VZV-infected**

733 **human trigeminal ganglia. a** Detection of VLT, canonical ORF63 and VLT-ORF63 isoforms

734 by RT-qPCR analysis in latently VZV-infected human trigeminal ganglia (TG) (n=4; post-

735 mortem interval 4 - 4.5 hr). Data on individual TG samples are shown as unique symbols.

736 **b** Detection of VZV ORF63 and VLT RNA by multiplex fluorescent *in situ* hybridization

737 (ISH) on human TG (upper two panels) and human herpes zoster skin biopsy (bottom
738 panel). Asterisks indicate autofluorescent lipofuscin granules in neurons. Arrowheads
739 indicate ORF63 (red) and/or VLT (green) ISH signal. Right panels: enlargements of area
740 indicated by white box. **c** Putative transcription start sites (TSS) of VLT (row 1, blue
741 arrows), VLT-ORF63 (row 2, green arrows) in human TGs and VLT in latently VZV-infected
742 HSN (row 3, red arrows), as determined by 5'-RACE analysis. Schematic top shows major
743 latent VLT and VLT-ORF63 transcript isoforms and location of primers used for 5'-RACE
744 analysis. Bottom: VLT sequence of VLT exon 1, as previously determined by RNA-seq on
745 human TGs⁷. Flanking regions are shown with arrows indicating putative TSS by 5'-RACE
746 analysis.

747

748 **Figure 3. Protein coding potential of VLT-ORF63 fusion transcripts.** **a** Schematic
749 presentation of VLT and VLT-ORF63 isoform transcripts with predicted encoded proteins.
750 White boxes with solid line indicate common exons of lytic and latent isoforms of VLT
751 and VLT-ORF63 transcripts, a box with dotted line indicates exon A of the lytic isoforms
752 and a black box indicates a part of ORF63 5'-UTR in canonical ORF63 transcript. The end
753 of VLT-ORF63 transcripts indicates stop codon for ORF63 CDS. Black horizontal lines
754 indicate location of encoded open reading frames (ORFs). Blue square indicates first start
755 codon, red triangle indicates first stop codon, green diamond indicates start codon of
756 canonical ORF63, and grey circle indicates downstream ATG sequences. Pointed
757 rectangles show translated protein from corresponding ORFs with a black box indicating
758 the 24 amino acid linker peptides translated from a part of ORF63 5'-UTR in the canonical

759 ORF63 transcript. UTR; untranslated region, CDS; coding sequence. **b-d** Confocal
760 microscopic images of ARPE-19 cells **b** transfected with CS-CA-VZV plasmids (48 hr post-
761 transfection), **c** lytically infected with VZV (4 dpi), and **d** herpes zoster skin lesions. **b, c**
762 Cells were stained with anti-pORF63 mAb (green) and anti-pORF63 pAb (red) for CS-CA-
763 ORF63, and anti-pVLT-ORF63 pAb (green), anti-pVLT pAb (red) and anti-pORF63 mAb
764 (blue) for CS-CA-VLT-ORF63a and CS-CA-VLT-ORF63b and lytic VZV infection. Nuclei were
765 stained with DAPI (cyan) and images are representative of results from two independent
766 experiments. Magnification; x600 and x3 digital zoom with 5 μm scale bars and x600 and
767 x2 digital zoom with 10 μm scale bars. **d** Nuclei were stained with DAPI (blue) and images
768 are representative for two independent stainings performed on one control and two
769 herpes zoster skin biopsies. Magnification: x200 with 50 μm scale bars and x200 and x3
770 digital zoom with 20 μm scale bars.

771

772 **Figure 4. Effect of anisomycin treatment on VZV transcription in latently VZV-infected**
773 **sensory neurons in vitro.** **a** RT-qPCR analysis for transcription across VLT and ORF63 loci
774 in latently VZV-infected HSN cultures (n=3). Data on individual HSN culture experiments
775 are shown as unique symbols. **b, c** Latently VZV-infected HSN cultures were depleted of
776 neurotropic factors (NGF, GDNF, BDNF and NT-3) and treated with anti-NGF antibody
777 (Ab) for 14 days. In total, n=40 independent cultures were subjected to reactivation and
778 one representative example of a HSN culture showing complete reactivation (black circle
779 in **c**) and early reactivation (white circle in **c**) by **b** infectious focus forming assay after
780 transferring HSN onto ARPE-19 cells and **c** RT-qPCR analysis using HSN. **d, e** HSN cultures

781 were treated with **d** anisomycin (n= 3), or **e** DMSO as solvent control (n= 2) at both the
782 somal and axonal compartment for 1 hr, washed twice and cultured for 7 days before RT-
783 qPCR analysis. Data on individual HSN culture experiments are shown as unique symbols.
784 Only VLT exon1-2 is shown as representative of VLT.

785

786 **Figure 5. Effect of ectopic VLT-ORF63 expression on VZV gene expression in latently**
787 **VZV-infected sensory neurons in vitro.** At 14 days after establishment of VZV latency in
788 HSN, following VZV genes were transduced by replication incompetent lentivirus
789 vectors: **a** empty vector, **b** ORF63, **c** VLT-ORF63b and **d** VLT-ORF63a. Transduced cells
790 were cultured for 14 days (n=4 replicates/vector) and subjected to RT-qPCR analysis.
791 Technical duplicates were utilized per sample and two biologically independent data is
792 shown.

793

794 **Supplementary Figure 1. Location of primer sets detecting transcripts from VLT and**
795 **ORF63 loci.** Schematics of major transcripts from VLT and ORF63 loci are shown in color:
796 lytic VLT isoform (red), latent VLT isoform (orange), canonical ORF63 (light green) and
797 lytic VLT-ORF63 isoforms (purple). Location of primer sets used for RT-qPCR analysis to
798 detect transcripts from VLT and ORF63 loci are depicted.

799

800 **Supplementary Figure 2. Detection of VZV ORF63 and VLT RNA by fluorescent multiplex**
801 **in situ hybridization.** Detection of VZV ORF63 and VLT RNA by multiplex fluorescent *in*
802 *situ* hybridization (mFISH) on **a** lytically VZV-infected ARPE-19 cells and **b** latently VZV-

803 infected human TG. **a, b** Right panels represent enlargements of area indicated by white
804 box. **b** Rare detection of ORF63 (red) and VLT (green) as discrete puncta in nuclei of
805 human TG neurons. Asterisks indicate autofluorescent lipofuscin granules in neurons
806 and arrowheads indicate ORF63 and/or VLT mFISH signal. **c** Human TG were stained with
807 mFISH using positive [UBC (red) and MALAT1 (green)] and negative control probes (DAPB,
808 green) to demonstrate specificity of the mFISH assay and RNA integrity of the tissue
809 assayed. Nuclei were stained with Hoechst (blue).

810

811 ***Supplementary Figure 3. In silico translation of VLT, canonical ORF63 and VLT-ORF63***

812 ***fusion transcripts.*** Amino acid (aa) sequence of VLT protein (pVLT; encoded by VLT or
813 VLT-ORF63b), ORF63 protein (pORF63; encoded by ORF63 or VLT-ORF63c), VLT-ORF63
814 protein (pVLT-ORF63; encoded by VLT-ORF63a) and pORF63-N+ (encoded by VLT-
815 ORF63b). The sequence of 24 aa peptide used as immunogen to generate the chicken
816 anti-pVLT-ORF63 polyclonal antibody is highlighted in grey color.

817

818 ***Supplementary Figure 4. Protein coding potential of VLT-ORF63 fusion transcripts.***

819 Immunoblotting analysis using antibodies directed to pVLT and pORF63 in the context of
820 mock- or VZV-infection in CS-CA-empty or CS-CA-VZV transfected ARPE-19 cells. Red
821 squares indicate pVLT-ORF63 (45.989-kDa), green triangles indicate pVLT (14.728-kDa),
822 blue circle indicates pORF63 (30.494-kDa) and purple diamonds indicate pORF63-N+
823 (40.723-kDa). Images are representative of two independent experiments. Molecular
824 weight marker (kDa) is shown in left.

825

826 ***Supplementary Figure 5. Transduced HSN express ectopic proteins encoded by***

827 ***replication incompetent lentivirus vectors.*** Confocal analysis using antibodies against

828 pORF63 and pVLT in HSN transduced with replication incompetent lentivirus vectors

829 encoding the following ORFs: **a** no gene (empty), **b** ORF63, **c** VLT-ORF63a or **d** VLT-ORF63b.

830 HSN cultures were matured for 49 days and transduced with each vector for 14 days.

831 The signal obtained with anti-pORF63 mAb staining was observed in the nucleus of both

832 ORF63- and VLT-ORF63-transduced HSN, in cytoplasm of ORF63-transduced HSN, but

833 undetectable in HSN transduced with empty vector or VLT-ORF63b. The anti-pVLT pAb

834 showed a nonspecific cytoplasmic signal in all transduced HSN, including 'empty', and

835 was too strong to determine if pVLT alone is expressed by VLT-ORF63b transduction.

836 Nuclear specific signal by anti-pVLT pAb was only detected in VLT-ORF63a-transduced

837 HSN and co-localized with the pORF63 signal, indicating nuclear expression of pVLT-

838 ORF63.

839





Figure 1. Transcription profile across the VLT and ORF63 loci during lytic VZV infection of human sensory neurons and epithelial cells. **a** Coverage plots denoting dRNA-Seq (ARPE-19 epithelial cells, dark blue) and cDNA-seq (HSN, light blue) data aligned to the top strand of the VZV genome. dRNA-Seq data is representative of two independently sequenced biological replicates with RNA was extracted from lytically VZV-infected ARPE-19 cells at 4 days post-infection (4 dpi). cDNA-Seq data was generated from a pool of biological replicates collected from lytically-infected HSN at 14 dpi. Schematics of the major transcripts from VLT and ORF63 loci are shown in following colors: lytic VLT isoform (red), canonical ORF63 (light green), lytic VLT-ORF63 isoforms (purple) and latent VLT isoform (orange). **b** Analysis of VLT, ORF63 and VLT-ORF63 isoform expression by RT-qPCR analysis using the same two independent experiments in ARPE-19 cells (black) and HSN (white) for long read sequencing. Data represent mean \pm SEM (standard error of mean). The primer location used for RT-qPCR analysis detecting transcripts from VLT to ORF63 loci are depicted in Supplementary Figure 1.




Figure 2. Transcription profile across the VLT and ORF63 loci in latently VZV-infected human trigeminal ganglia.

a Detection of VLT, canonical ORF63 and VLT-ORF63 isoforms by RT-qPCR analysis in latently VZV-infected human trigeminal ganglia (TG) (n=4; post-mortem interval 4 - 4.5 hr). Data on individual TG samples are shown as unique symbols. **b** Detection of VZV ORF63 and VLT RNA by multiplex fluorescent *in situ* hybridization (ISH) on human TG (upper two panels) and human herpes zoster skin biopsy (bottom panel). Asterisks indicate autofluorescent lipofuscin granules in neurons. Arrowheads indicate ORF63 (red) and/or VLT (green) ISH signal. Right panels: enlargements of area indicated by white box. **c** Putative transcription start sites (TSS) of VLT (row 1, blue arrows), VLT-ORF63 (row 2, green arrows) in human TGs and VLT in latently VZV-infected HSN (row 3, red arrows), as determined by 5'-RACE analysis. Schematic top shows major latent VLT and VLT-ORF63 transcript isoforms and location of primers used for 5'-RACE analysis. Bottom: VLT sequence of VLT exon 1, as previously determined by RNA-seq on human TGs⁷. Flanking regions are shown with arrows indicating putative TSS by 5'-RACE analysis.






Figure 3. Protein coding potential of VLT-ORF63 fusion transcripts. **a** Schematic presentation of VLT and VLT-ORF63 isoform transcripts with predicted encoded proteins. White boxes with solid line indicate common exons of lytic and latent isoforms of VLT and VLT-ORF63 transcripts, a box with dotted line indicates exon A of the lytic isoforms and a black box indicates a part of ORF63 5'-UTR in canonical ORF63 transcript. The end of VLT-ORF63 transcripts indicates stop codon for ORF63 CDS. Black horizontal lines indicate location of encoded open reading frames (ORFs). Blue square indicates first start codon, red triangle indicates first stop codon, green diamond indicates start codon of canonical ORF63, and grey circle indicates downstream ATG sequences. Pointed rectangles show translated protein from corresponding ORFs with a black box indicating the 24 amino acid linker peptides translated from a part of ORF63 5'-UTR in the canonical ORF63 transcript. UTR; untranslated region, CDS; coding sequence. **b-d** Confocal microscopic images of ARPE-19 cells **b** transfected with CS-CA-VZV plasmids (48 hr post-transfection), **c** lytically infected with VZV (4 dpi), and **d** herpes zoster skin lesions. **b, c** Cells were stained with anti-pORF63 mAb (green) and anti-pORF63 pAb (red) for CS-CA-ORF63, and anti-pVLT-ORF63 pAb (green), anti-pVLT pAb (red) and anti-pORF63 mAb (blue) for CS-CA-VLT-ORF63a and CS-CA-VLT-ORF63b and lytic VZV infection. Nuclei were stained with DAPI (cyan) and images are representative of results from two independent experiments. Magnification; x600 and x3 digital zoom with 5 μ m scale bars and x600 and x2 digital zoom with 10 μ m scale bars. **d** Nuclei were stained with DAPI (blue) and images are representative for two independent stainings performed on one control and two herpes zoster skin biopsies. Magnification: x200 with 50 μ m scale bars and x200 and x3 digital zoom with 20 μ m scale bars.




Figure 4. Effect of anisomycin treatment on VZV transcription in latently VZV-infected sensory neurons in vitro. **a** RT-qPCR analysis for transcription across VLT and ORF63 loci in latently VZV-infected HSN cultures (n=3). Data on individual HSN culture experiments are shown as unique symbols. **b, c** Latently VZV-infected HSN cultures were depleted of neurotrophic factors (NGF, GDNF, BDNF and NT-3) and treated with anti-NGF antibody (Ab) for 14 days. In total, n=40 independent cultures were subjected to reactivation and one representative example of a HSN culture showing complete reactivation (black circle in **c**) and early reactivation (white circle in **c**) by **b** infectious focus forming assay after transferring HSN onto ARPE-19 cells and **c** RT-qPCR analysis using HSN. **d, e** HSN cultures were treated with **d** anisomycin (n= 3), or **e** DMSO as solvent control (n= 2) at both the somal and axonal compartment for 1 hr, washed twice and cultured for 7 days before RT-qPCR analysis. Data on individual HSN culture experiments are shown as unique symbols. Only VLT exon 1-2 is shown as representative of VLT.




Figure 5. Effect of ectopic VLT-ORF63 expression on VZV gene expression in latently VZV-infected sensory neurons *in vitro*. At 14 days after establishment of VZV latency in HSN, following VZV genes were transduced by replication incompetent lentivirus vectors: **a** empty vector, **b** ORF63, **c** VLT-ORF63b and **d** VLT-ORF63a. Transduced cells were cultured for 14 days (n=4 replicates/vector) and subjected to RT-qPCR analysis. Technical duplicates were utilized per sample and two biologically independent data is shown.